IRVINE, Calif. -- Edwards Lifesciences Corp. said Wednesday it completed its acquisition of Bmeye BV, a Dutch company that develops products used in monitoring blood circulation and heart function, for about $42 million.
Edwards said that Bmeye develops non-invasive technology that can be used in surgical, intensive care, emergency room, and cardiology settings.
Irvine, Calif.-based Edwards said the acquisition won't affect its income in 2012 and will cause a small reduction to its net income in 2013.
Shares of Edwards Lifesciences rose $3.30, or 3.9 percent, to $87.90 in midday trading.
They bounced back after plunging 21 percent Tuesday when it issued a disappointing third-quarter revenue forecast that included lower-than-expected sales of its Sapien heart valve. But they are still 21 percent below their 52-week high of $110.79 reached earlier this month.